Cardiff Oncology CFO granted 486,650 stock options
Cardiff Oncology, Inc. Chief Financial Officer Joshua B. Muntner reported a compensation-related grant of 486,650 stock options on April 6, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cardiff Oncology, Inc. Chief Financial Officer Joshua B. Muntner reported a compensation-related grant of 486,650 stock options on April 6, 2026. These options allow him to purchase common stock at an exercise price of $1.58 per share and expire on April 6, 2036.
According to the vesting terms, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months thereafter. Following the grant, he holds 487,150 stock options and 500 shares of common stock, all reported as directly owned.
Insider Trade Summary
Grant/Award: 486,650 shares
Grant/Award
2 txns
Insider
Muntner Joshua B
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 486,650 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Options — 487,150 contracts (Direct);
Common Stock — 500 shares (Direct)
Footnotes (1)
- F1. 121,663 vest on April 6, 2027 and 10,139 vest monthly for 36 months thereafter.
Key Figures
Options granted: 486,650 stock options
Exercise price: $1.58 per share
Options expiration: April 6, 2036
+4 more
7 metrics
Options granted
486,650 stock options
Grant to CFO on April 6, 2026
Exercise price
$1.58 per share
Strike price for granted options
Options expiration
April 6, 2036
Expiration date of granted options
Initial vesting tranche
121,663 options
Vest on April 6, 2027
Monthly vesting amount
10,139 options
Vest monthly for 36 months after April 6, 2027
Options after transaction
487,150 stock options
Total options held following grant
Common shares held
500 shares
Direct common stock holdings after transaction
Key Terms
Stock Options, exercise price, vesting, expiration date, +1 more
5 terms
Stock Options financial
"security_title": "Stock Options""
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"conversion_or_exercise_price": "1.5800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"121,663 vest on April 6, 2027 and 10,139 vest monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date": "2036-04-06T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title": "Common Stock""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cardiff Oncology (CRDF) disclose about its CFO’s Form 4 transaction?
Cardiff Oncology reported that CFO Joshua B. Muntner received a grant of 486,650 stock options on April 6, 2026. The options are compensation-related, not an open-market purchase, and give him the right to buy common shares at a fixed exercise price.
How many stock options did the Cardiff Oncology (CRDF) CFO receive and at what price?
The CFO received 486,650 stock options with an exercise price of $1.58 per share. These options relate to Cardiff Oncology common stock and provide the right, but not obligation, to purchase shares at that price before expiration.
What is the vesting schedule for the Cardiff Oncology (CRDF) CFO stock options?
Of the granted options, 121,663 vest on April 6, 2027, and 10,139 vest monthly for 36 months after that date. This staggered vesting structure ties compensation to continued service over several years.
When do the newly granted Cardiff Oncology (CRDF) stock options expire?
The reported stock options granted to the CFO expire on April 6, 2036. This long-dated expiration gives a multi-year window during which vested options can be exercised at the $1.58 per share strike price.
How many Cardiff Oncology (CRDF) securities does the CFO hold after this Form 4?
After the reported grant, the CFO holds 487,150 stock options and 500 shares of common stock, all listed as directly owned. These figures show his reported derivative and share position as of the transaction date.
Is the Cardiff Oncology (CRDF) CFO Form 4 a stock purchase or a grant?
The Form 4 reflects a grant or award acquisition of stock options, coded as “A,” rather than an open-market stock purchase. It is a compensation award that establishes potential future share purchases at a set exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates